Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP001 Phase 2 Study in ALS
NCT01281631Phase 2Completed
- Sponsor
- Neuraltus Pharmaceuticals
- Start
- Feb 2011
- Primary completion
- Sep 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of sodium chlorite in amyotrophic lateral sclerosis (ALS), sponsored by Neuraltus Pharmaceuticals. Started Feb 2011; status: completed.
02
Drugs
sodium chlorite
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01281631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281631.